Rapid Regulatory Path

The most likely path is that the sponsor moves quickly toward US and European filings for a lutetium-177 peptide therapy, likely ITM-11 if the report concerns ITM's late-stage asset. Recent Pluvicto label expansion and Telix's agreement to acquire ITM make regulators and investors more receptive to radiopharmaceutical oncology, provided manufacturing and safety data are clean.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.